| Authors: |
Moreau C; Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France., Odou P; GRITA ULR 7365, University of Lille, Lille, France.; Pharmacy CHU Lille, Lille, France., Labreuche J; Department of Biostatistics, University of Lille, CHU de Lille, Lille, France., Demailly A; InBrain Pharma, Lille, France., Touzet G; Neurosurgery Department, University of Lille, CHU Lille, Lille, France., Reyns N; Neurosurgery Department, University of Lille, CHU Lille, Lille, France., Gouges B; Neurosurgery Department, University of Lille, CHU Lille, Lille, France., Duhamel A; Department of Biostatistics, University of Lille, CHU de Lille, Lille, France., Barthelemy C; Pharmacy CHU Lille, Lille, France., Lannoy D; GRITA ULR 7365, University of Lille, Lille, France.; Pharmacy CHU Lille, Lille, France., Carta N; Pharmacy CHU Lille, Lille, France., Palas B; Pharmacy CHU Lille, Lille, France., Vasseur M; Pharmacy CHU Lille, Lille, France., Marchand F; Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France., Ollivier T; Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France., Leclercq C; Clinical Studies Pharmacovigilance Department, CHU Lille, Lille, France., Potey C; Clinical Studies Pharmacovigilance Department, CHU Lille, Lille, France., Ouk T; Clinical Studies Pharmacovigilance Department, CHU Lille, Lille, France., Baigne S; InBrain Pharma, Lille, France., Dujardin K; Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France., Carton L; Department of Medical Pharmacology, University of Lille, INSERM, CHU Lille, U1172-Degenerative & Vascular Cognitive Disorders, LilNCog, Lille Neuroscience & Cognition, LICEND, NS-Park Network, Lille, France., Rolland AS; Department of Medical Pharmacology, University of Lille, INSERM, CHU Lille, U1172-Degenerative & Vascular Cognitive Disorders, LilNCog, Lille Neuroscience & Cognition, LICEND, NS-Park Network, Lille, France., Devedjian JC; Department of Medical Pharmacology, University of Lille, INSERM, CHU Lille, U1172-Degenerative & Vascular Cognitive Disorders, LilNCog, Lille Neuroscience & Cognition, LICEND, NS-Park Network, Lille, France., Foutel V; InBrain Pharma, Lille, France., Deplanque D; Clinical Studies Pharmacovigilance Department, CHU Lille, Lille, France.; University of Lille, INSERM, CHU Lille, CIC 1403-Centre d'investigation Clinique, Lille, France., Fisichella M; InBrain Pharma, Lille, France., Devos D; Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France. david.devos@chru-lille.fr.; Department of Medical Pharmacology, University of Lille, INSERM, CHU Lille, U1172-Degenerative & Vascular Cognitive Disorders, LilNCog, Lille Neuroscience & Cognition, LICEND, NS-Park Network, Lille, France. david.devos@chru-lille.fr. |
